Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.38 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136113 | 0.90 | TRPV1 (0.52) | TRPV1ESR1ESR2MT-CO2HCAR2 | |
| SCHEMBL6136359 | 0.85 | KMT2A (0.53) | TRPV1MTORMT-CO2MEN1RAB9A | |
| SCHEMBL6136341 | 0.84 | MTOR (0.53) | TRPV1MTORESR1ESR2ABCC1 | |
| SCHEMBL6136478 | 0.84 | MTOR (0.48) | TRPV1MTORESR1ESR2 | |
| SCHEMBL6136147 | 0.84 | MTOR (0.61) | TRPV1MTORESR1ESR2ABCC1 | |
| SCHEMBL6136177 | 0.83 | MTOR (0.49) | TRPV1MTORESR1ESR2KMT2A | |
| SCHEMBL6136098 | 0.80 | ESR1 (0.39) | TRPV1MTORESR1ESR2MT-CO2 | |
| SCHEMBL6136139 | 0.79 | MTOR (0.47) | TRPV1MTORESR1ESR2MAPT | |
| SCHEMBL6136211 | 0.77 | ESR1 (0.38) | TRPV1MTORESR1ESR2MT-CO2 | |
| SCHEMBL6136358 | 0.74 | TRPV1 (0.43) | TRPV1ESR1ESR2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0895989-B1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | LILLY CO ELI (US) | 2005-05-18 | — | — | EP | claimed |
| US-6509356-B1 | Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound | ELI LILLY AND COMPANY | 2003-01-21 | — | — | US | claimed |
| EP-0895989-A1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | claimed |
| EP-0895989-B1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | LILLY CO ELI (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6509356-B1 | Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound | ELI LILLY AND COMPANY | 2003-01-21 | — | — | US | disclosed |
| EP-0895989-A1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | disclosed |